Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Current Assets data on record, last reported at $1.8 billion in Q1 2026.

  • On a quarterly basis, Current Assets rose 5.65% to $1.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.8 billion, a 5.65% increase, with the full-year FY2025 number at $1.6 billion, down 8.98% from a year prior.
  • Current Assets reached $1.8 billion in Q1 2026 per PCVX's latest filing, up from $1.6 billion in the prior quarter.
  • Over the last five years, Current Assets for PCVX hit a ceiling of $2.2 billion in Q3 2024 and a floor of $342.2 million in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.5 billion in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 267.69% in 2022, then decreased 20.18% in 2025.
  • Tracing PCVX's Current Assets over 5 years: stood at $942.6 million in 2022, then increased by 16.27% to $1.1 billion in 2023, then skyrocketed by 63.14% to $1.8 billion in 2024, then fell by 8.98% to $1.6 billion in 2025, then rose by 11.44% to $1.8 billion in 2026.
  • Business Quant data shows Current Assets for PCVX at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.8 billion in Q3 2025.